Chronic inflammatory demyelinating polyradiculoneuropathy is a rare autoimmune-related condition that affects nerve signaling ...
CINCINNATI (WKRC) - Sasha Uhl, a wife and mother, is cherishing the holiday season with her family after a rare illness nearly claimed her life this past year. Sasha, who is celebrating with her ...
Argenx SE gained U.S. FDA approval of subcutaneously given Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Shares of argenx ARGX rose nearly 4% on Friday after management announced that the FDA approved its subcutaneously administered Vyvgart Hytrulo (efgartigimod) for a second indication — chronic ...
Investor's Business Daily on MSN
Dianthus Therapeutics has appreciated 12-fold over two years. What's going on?
Dianthus Therapeutics stock shot higher Monday after the company said it would advance its experimental CIDP treatment.
Dianthus Therapeutics Inc. DNTH shares are up during Monday’s premarket session following an early GO decision announced by the company based on an interim responder analysis in the Phase 3 CAPTIVATE ...
An engineer sought a neurologist's opinion after an AI suggested a rare disorder. Despite normal tests, the patient insisted on a specific treatment based on the AI's diagnosis. This case shows how AI ...
The US Food and Drug Administration (FDA) has approved the combination of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) for treatment of adults with chronic inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results